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What’s Known on This Subject 
Little is known about the pharmacokinetics of potassium canrenoate/canrenone in 
paediatric patients 
 
What This Study Adds 
A population pharmacokinetic model has been developed to evaluate the 
pharmacokinetics of canrenone in paediatric patients who received potassium 
canrenoate as part of their therapy in the intensive care unit.  
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Abstract 
Objectives: To characterize the population pharmacokinetics of canrenone following 
administration of potassium canrenoate in paediatric patients. 
Patients and Methods: Data were collected prospectively from 23 paediatric patients (2 
days to 10 years of age; median weight 4 kg, range 2.16-28.0 kg) who received 
intravenous potassium canrenoate (K-canrenoate) as part of their intensive care therapy 
for removal of retained fluids e.g. in pulmonary oedema due to chronic lung disease and 
for the management of congestive heart failure. Plasma samples were analysed by 
HPLC for determination of canrenone (the major metabolite and pharmacologically active 
moiety) and the data subjected to pharmacokinetic analysis using NONMEM. 
Results: A one-compartment model best described the data. The only significant 
covariate was weight (WT). The final population models for canrenone clearance (CL/F) 
and volume of distribution (V/F) were CL/F (L/hr) = 11.4 × (WT /70.0)0.75 and V/F (L) = 
374.2 × (WT/70) where WT is in kg. The values of CL/F and V/F in a 4 kg child would be 
1.33 L/hr and 21.4 L, respectively, resulting in an elimination half-life of 11.2 hr.  
Conclusions: The range of estimated CL/F in the study population was 0.67 - 7.38 L/hr. 
The data suggest that adjustment of K-canrenoate dosage according to body weight is 
appropriate in paediatric patients. 
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Introduction 
Spironolactone and potassium canrenoate (K-canrenoate), are commonly used in 
paediatric patients with clinical disorders such as pulmonary oedema, congestive heart 
failure and hypertension1,2. Because of its low solubility in aqueous fluids, spironolactone 
is only available in per-oral formulation for clinical use. Tablets are licensed in the UK for 
use in children ≥1 year. An oral suspension may be extemporaneously prepared by 
crushing tablets or obtained as a ‘specials’ formulation and as such is an unlicensed use.  
K-canrenoate is the potassium salt of the γ-hydroxy acid, obtained by opening the 
lactone ring of canrenone, the major dethioacetylated metabolite of spironolactone. 
Because of its aqueous solubility, K-canrenoate, is used as an injectable aldosterone 
antagonist with similar therapeutic activity to spironolactone3,4,5. It is not licensed for use 
in children or neonates in the UK but is frequently used for short-term parenteral 
treatment in paediatric patients when oral treatment with spironolactone is difficult or not 
possible6. 
Much of the available information relating to dosage of diuretics in paediatric patients, in 
particular neonates, is derived from studies conducted in adults1. Doses of 
spironolactone (0.7 x potassium canrenoate) have been proposed2,6,7 taking account of 
the higher potency of spironolactone on a mg basis.  
Despite the relatively widespread use of spironolactone and K-canrenoate in paediatric 
patients, there are no available data on the pharmacokinetics of these two medications in 
this population. In 2003, spironolactone was placed on the US National Institute of 
Health’s list of drugs requiring paediatric investigation8 and in 2007, it was also included 
in the European Medicines Agency’s priority list of off-patent medicines that require 
assessment in children9. 
Therefore, the aim of the present study was to investigate the pharmacokinetics of A
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canrenone after IV administration of K-canrenoate to neonates/infants/children for 
management of retained fluids (e.g. due to chronic lung disease or congestive heart 
failure). 
Patients and Methods  
Patients and data collection  
The study was approved by the Research Ethics Committee, Queen’s University Belfast 
and written informed consent was obtained from each patient’s legal guardian before 
enrolment in the study; assent was also obtained from children ≥8 years. Samples and 
patient data were collected prospectively from 23 neonates/infants/children who received 
intravenous K-canrenoate as part of their care in the NICU at the Royal Jubilee Maternity 
Service, Belfast or in the medical and intensive care wards at the Royal Belfast Hospital 
for Sick Children. Dosage regimens used were those deemed appropriate by the treating 
clinicians.  
A maximum of eight samples were collected from each patient, usually when blood was 
being withdrawn for routine laboratory analyses. However, ethical approval allowed 
additional samples to be taken at the discretion of the research nurse provided an 
indwelling catheter was in place. Blood samples, collected in EDTA sample tubes, were 
centrifuged at 1800g for 10 min; the plasma fraction was transferred to a clean sample 
tube and stored at -20°C until analysis.  
Data on date and time of sampling and date and time of previous K-canrenoate doses 
were recorded for each sample. The following data were collected from each patient’s 
medical notes: weight (WT), gestational age (GA), postnatal age (PNA), gender, serum 
creatinine, serum albumin, haematocrit and concomitant medications.  
Response to treatment A
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In order to assess effectiveness of K-canrenoate treatment, the following 
pharmacodynamic measures were recorded for all patients at the time of each sample: 
respiratory rate, heart rate, mean blood pressure and sodium and potassium levels. 
Furthermore, the association between these measures and measured canrenone 
concentrations were examined. 
Drug analysis  
A selective and sensitive HPLC method with UV detection for measuring plasma 
concentrations of canrenone, the active metabolite of K-canrenoate, was developed and 
validated10. The limits of detection and quantification were 6.0 ng/mL and 25.0 ng/mL 
respectively. Intra-day accuracy (mean RE%) ranged from -1.7 to +6.0% while the 
imprecision lay between 2.1 and 11.4% relative standard deviation (RSD). Inter-day 
accuracy ranged from -7.2 to +4.8%, with imprecision between 2.4 and 12.6% RSD. 
Population pharmacokinetic modelling  
Population pharmacokinetic analysis was performed by means of nonlinear mixed-effect 
modelling using first-order conditional estimation with interaction (NONMEM® version VI, 
level 1.0)11. 
Step 1  
The complete dataset was used for development of the pharmacokinetic model. Potential 
models considered were classical linear one-and two-compartment models. The 
pharmacokinetic parameters estimated from these models (implemented using PREDPP 
subroutine ADVAN6) were CL/F and V/F for canrenone and the metabolic transformation 
rate constant of K-canrenoate into canrenone (Kf). The relationship between the parent 
drug and its metabolite was defined according to the following equations: A
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d A(K-canrenoate) = A(K-canrenoate)
dt f
k− ×  
d A(canrenone) = A(K-canrenoate) A(canrenone)
dt f e
k k× − ×  
Where kf is the metabolic transformation rate constant of K-canrenoate into canrenone 
and ke is the elimination rate constant of canrenone. Canrenone can be converted back 
to canrenoic acid through hydrolysis or be further metabolised and excreted in urine (see 
Figure 1). The pharmacokinetic parameters estimated here were based on the 
assumption that the total dose of K-canrenoate is converted into canrenone. 
Interindividual variability (IIV) in each pharmacokinetic parameter (CL/F and V/F) was 
estimated using an exponential scale since they must be constrained to be greater than 
zero and their distribution is often right skewed12.   
Proportional and additive components of residual variability were estimated throughout 
model development, as follows:  
( ) ijAijpijpredij CC ,,, 1 εε ++×=  
Simplification was considered during the model building by deleting the residual variance 
component with a value close to zero.  
Weight was included as an a priori covariate on CL/F and V/F in the basic 
pharmacokinetic model and was scaled to 70 kg. Values were adjusted for weight using 
fixed exponents of 0.75 for CL/F and 1 for V/F as follows13-14.  
( )0.75CL/F / 70i CL iWTθ= ×  
 ( )V/F / 70i V iWTθ= ×  A
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However, and due to the fact that most of the children in the present study were 
neonates and infants less than 1 year-old, the allometric model exponents were also 
experimentally determined as additional thetas (θs) and the results compared with those 
obtained when fixed exponents were used. 
Step 2 
Visual examination of scatter plots (or box-and-whisker plots in the case of categorical 
covariates) of individual Bayesian estimates and IIV variability (ETAs) obtained for each 
pharmacokinetic parameter from Step 1 versus each covariate were used to help identify 
whether the pharmacokinetic parameter might be significantly related to the covariate. 
Direct covariate testing was then performed to see if this relationship was significant.  
Step 3  
The final model was established using the forward inclusion–backward elimination 
method15. Forward inclusion of a covariate required a reduction in the minimum value of 
the objective function (MOFV) of at least 6.63, (p<0.01, df=1). During stepwise backward 
elimination a more stringent criterion of statistical significance was required and a 
covariate was retained in the model only if the MOFV increased at least 10.83 units 
(p<0.001, df=1) when removed. 
Graphical inspection of goodness-of-fit was used throughout model building and 
evaluation16. Visual predictive check (VPC) plots were generated using PsN 
(http://psn.sourceforge.net) and plotted using Xpose® (http://xpose.sourceforge.net) to 
assess the deviations of model-predicted from observed concentrations when fixed or 
experimentally-determined exponents were used. In addition, internal validation of the 
final model was undertaken using the technique of bootstrapping (Wings for NONMEM, 
version 611, http://wfn.sourceforge.net/index.html).  A
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Influence analysis 
Influence analysis was carried out to assess stability of the final model parameters 
towards influential subjects17. This involved generating a series of new datasets where a 
unique subject was removed from each one (i.e. jack-knifed datasets). The final model 
was re-fitted to each of the new datasets. The percent change in parameter estimates 
obtained from each dataset, relative to parameter estimates obtained from the original 
dataset, was then calculated.  
To test the overall influence of any individual on the model parameters, the jack-knifed 
matrix of structural model parameters and variance components was subjected to 
principal component analysis (PCA)17 using SPSS
® 
(version 17.0) for Windows. 
Statistical Analysis 
Univariate analysis was performed using SPSS® for windows (version 17.0; SPSS Inc., 
Chicago, IL, USA). The Spearman Rho (ρ) test was performed to determine the 
association between the various pharmacodynamic measures recorded at each 
sampling time and canrenone plasma concentrations. Two-tailed p-values of <0.05 were 
considered statistically significant. 
Results  
Patients and Data Collection 
A total of 23 paediatric patients with a median body weight of 4 kg (2.16-28.0 kg) were 
enrolled in the study. Characteristics of the study subjects are presented in Table 1; 20 
patients were <1 year, the others being 2, 6 and 10 years. The pharmacokinetic analysis 
was carried out on the complete data set without excluding any of the patients. The final 
population pharmacokinetic model obtained from the original dataset, however, was re-
fitted to a reduced dataset which contained only children < 1 year-old to examine the A
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influence of older patients on predicted CL. The population pharmacokinetic parameter 
estimates obtained from the two datasets were then compared.  
Response to Treatment 
In patients with congestive heart failure, the measured concentrations of canrenone were 
significantly associated with reduced mean blood pressure (p=0.003), a sign of 
improvement in heart failure. On the other hand, in cases where K-canrenoate treatment 
was administered for management of retained fluids in the intensive care unit, measured 
levels of canrenone were significantly associated with reduced sodium levels (p<0.001) 
and increased levels of potassium (p=0.037) reflecting a good response to treatment in 
these patients. 
 Pharmacokinetic Modelling 
NONMEM analysis was performed using 101 plasma concentrations from the 23 infants 
enrolled. Figure 2 shows the individual plasma canrenone concentrations against time 
relative to drug administration. The one-compartment model with first order metabolite 
formation and elimination adequately described the disposition of canrenone in plasma. 
The limited number of samples collected shortly after K-canrenoate administration did 
not enable accurate evaluation of the distribution phase and hence the 2-compartment 
model did not provide a better fit to the data.  
Since the additive term of residual error variance approached 0, it was removed resulting 
in a proportional error model that was considered adequate to describe residual 
variability. Only diagonal elements of the covariance matrix were estimated as population 
parameters were not highly correlated and exploration of the full covariance matrix 
resulted in a negligible decrease in MOFV.  
Weight was included as an a priori covariate on clearance and volume using both A
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allometric scaling with fixed and experimentally-determined power values. Investigation 
of models where the power values were not fixed, but included as additional thetas (θs), 
did not result in any significant improvement in model fit (Table 2). On the other hand, 
visual predictive checks created from these models showed slight model under-
prediction of carenone measured concentrations when exponents were determined 
separately (as two different thetas) or when one theta value was chosen for both CL and 
V exponents (Figure 3). Therefore, fixed exponents of 0.75 for CL and 1 for V were used 
in the present study. From the VPC plot, it appears that the model with fixed exponents 
exhibited no evidence of misspecification. 
Covariate screening and selection of the final model  
Initial screening did not reveal any potential strong relationships between either CL/F or 
V/F and any of the covariates. However, some plots showed two extreme values related 
to the two oldest patients. None of the age descriptors (GA, PNA, PMA) showed any 
significant effect when included in the base model. This is to be expected, since age and 
weight are known to be highly correlated covariates18.  
The final population pharmacokinetic model for disposition of canrenone in plasma was 
therefore the base model that included weight as an a priori covariate as shown:  
0.75WTCL/F (L/h)
70CL
θ ⎛ ⎞= ×⎜ ⎟⎝ ⎠  and 
WTV/F (L)
70V
θ ⎛ ⎞= ×⎜ ⎟⎝ ⎠  
where θCL and θV are the typical population estimates of CL/F and V/F in a hypothetical 
individual with weight (WT) equal to 70 kg. The condition number of the final model was 
adequate (24.48) indicating that the model estimates were stable and not influenced by 
ill-conditioning. The mean parameter estimates and their variances are presented in 
Table 3.  A
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Typical population estimates of CL/F and V/F were 11.4 L/hr/70 kg and 374.2 L/70 kg, 
respectively. The median weight in our population was 4kg; the corresponding values of 
CL/F and V/F in a 4 kg patient were therefore 1.33 L/hr and 21.4 L, respectively, with an 
elimination half-life (t1/2) of 11.2 hr.  
The IIVs (CV%) associated with CL/F and V/F in this model were 41.1% and 45.8% 
respectively. The residual variability (CV%) was 34.1%.  
The median, 5
th 
and 95
th 
percentiles, mean (standard deviation) and range of the 
empirical Bayesian estimates for CL/F and V/F in the study population (obtained from the 
final model) are shown in Table 4. The table also shows weight normalised values for 
these parameters and the predicted elimination t1/2. A review of the Bayesian estimates 
of CL for children older than 1 year, revealed that the oldest and the heaviest child within 
the group (10 years old, WT=28 kg) had the maximum value of predicted CL (7.38 L/hr). 
The other two patients, however, were not identified as having different CL from the rest 
of the population (estimated CL values were 3.6 and 2.9 L/hr for the 2 and 6 year-old 
patients, respectively). 
Model evaluation and validation  
Graphical evaluation  
Agreement between measured and model-predicted canrenone concentrations final 
models is illustrated in Figure 4. Plots from the final model are randomly scattered with 
no systematic deviation from the line of identity indicating that the model characterizes 
the overall behaviour of the data.  
Examination of residuals (Figure 5) indicates that the assumption of random effects was 
appropriate since both residuals and weighted residuals did not show any trend and 
were evenly distributed around zero in plots obtained from the final model. In addition, A
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almost all weighted residuals were contained within values of ±2 units of the null ordinate 
indicating absence of any influential observations.  
Influence analysis  
No subject had any profound effect on the model parameters. Generally, a subject may 
be considered influential when their removal from a dataset results in more than ±20 % 
change in parameter estimates17. In addition, no significant change in parameter 
estimates was seen when the final model was refitted to a dataset that involved only 
patients younger than one year. The mean population estimate of CL/F was very similar 
to that obtained from the original complete data set and the estimate of V/F was ~7% 
less. Therefore, there was no evidence that these subjects need to be removed from the 
analysis and the model was considered generally stable. 
Since the number of estimated parameters in the final model was not high, the generated 
matrix of standardized parameters (fixed effects and variance components) did not allow 
principle component analysis (PCA) to be carried out on each component alone19. 
However, when PCA was performed on the full matrix of parameters, no influential 
individuals were identified, confirming the results obtained above.  
Model validation  
Results from 1,000 bootstrap re-sampled datasets, for which 996 models converged 
successfully, are presented in Table 3 indicating that model parameters and variance 
components were precisely estimated with acceptable % difference (<15%).  
Lactonisation 
The transformation rate constant of K-canrenoate into canrenone, kf was estimated as 
5.25 hr-1, which represents a lactonisation t1/2 of 0.13 hr (7.8 min) and the elimination rate 
constant of canrenone, ke was estimated as 0.062 hr-1. These results indicate that A
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lactonisation occurred rapidly in paediatric patients. Based on these values, the time to 
reach maximum concentration of canrenone (Tmax) would be 0.85 hr (51 min); 
previously reported values of lactonisation t1/2 and time to reach maximum canrenone 
concentration in adults have been reported as 8±4 minutes and 29±15 minutes, 
respectively20. 
Discussion 
Using a sparse sampling approach, pharmacokinetic analysis of canrenone plasma 
concentration data, obtained following IV administration of K-canrenoate to neonates, 
infants and children, we have shown that disposition of canrenone is affected by weight 
of the patient. Weight influenced both CL/F and V/F using the power allometric model 
with fixed exponents (0.75 for CL/F and 1 for V/F).  
The IIV in CL/F and V/F was reduced from 69.64% to 41.06% and from 69.24% to 
45.76%, respectively by inclusion of weight in the model. However, none of the other 
studied covariates reduced IIV further; this may be due to the narrow range or uneven 
distribution of these covariates in the studied population.  
The population estimate for V/F in this study was 374.2 L (bodyweight 70 kg) which is 
much larger than plasma volume indicating that canrenone readily distributes into body 
tissues.  
The population estimate of canrenone plasma clearance in paediatric patients obtained 
in the current study (11.4 L/hr when scaled to a weight of 70 kg) is lower than previously 
reported values in adults (17.6±7.6 L/hr/70 kg)20. This indicates that there are age-related 
differences in canrenone clearance probably due to reduced renal and hepatic function, 
and a lower activity of the enzymes responsible for metabolism of canrenone in infants.  
Besides, in the study by Krause et al 20, the researchers suggested that the disposition of A
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canrenone in plasma in adults is triphasic, since a rapid α-phase (t1/2 = 41 min) was 
observed in one volunteer, a β-phase (t1/2 = 4 hr) was observed in all study volunteers 
(n=3) and a slow γ-phase (t1/2 = 10.5 hr) was observed in one volunteer. The estimate of 
canrenone t1/2 in plasma observed in the current study is higher than those previously 
reported values in adults. However, the results cannot be directly compared because of 
differences in the modelling approach and research methodology.  
When K-canrenoate is administered intravenously it is instantaneously converted in the 
body to canrenoic acid which is then either converted to the biologically active metabolite 
canrenone, or glucuronidated and excreted in the urine. Since canrenone was detected 
in all patients and the estimated lactonisation rate constant was comparable to that 
previously reported in adults, these findings indicate that plasma paraoxonase enzymes 
(PONs) responsible for lactonisation of canrenoic acid to canrenone (i.e. PON1 and 
PON3) are active in paediatric patients, including neonates. PON3 is also responsible for 
hydrolysis of spironolactone and canrenone.21 Genetic variation plays a role in 
determining levels of activity of PONs22 and serum PON1 activity is low at birth but 
increases to a plateau between 6 and 15 months of age23; both factors will therefore 
contribute to interindividual variability. Although we are unaware of reports regarding 
PON3 in children, our results suggest that it may be active in neonates and infants. 
In the present study, only K-canrenoate was administered and neither concentrations of 
parent drug nor concentrations of its glucuronidated metabolite were measured. To allow 
all parameters to be characterised in such a reversible system would require both K-
canrenoate and canrenone to be administered separately; concentrations of the two 
compounds could then be measured and the four concentration-time profiles evaluated24. 
This was not possible in the current research which was carried out within a normal 
clinical environment. In the present modelling, it was therefore necessary to assume that 
K-canrenoate was irreversibly converted to canrenone and estimated values of A
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clearance and volume were based on the assumption that the total dose of K-canrenoate 
was converted to canrenone. These estimated values should therefore be regarded as 
the upper limits of the true values.  
Conclusion 
The range of estimated CL/F in the study population was 0.67 - 7.38 L/hr, with the 
variance driven largely by body weight. The current practice of administering K-
canrenoate according to body weight therefore appears to be justified in the paediatric 
population. 
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Figure 1: Representation of the reversible metabolic conversion of canrenoic acid 
to canrenone  
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Figure 2: A plot of measured canrenone plasma concentrations versus time since 
dose administration. The solid thick line indicates the 50th percentile of measured 
plasma concentrations while the dashed lines indicate the 5th and 95th percentiles.  
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A B C
 
 
Figure 3: Visual predictive check plots for models using fixed and experimental exponents; (A) a model with fixed exponents of 0.75 
for CL and 1 for V (B) a model with two experimentally determined thetas (one for each exponent) (c) a model with one experimentally 
theta for both exponents. Solid (–) and dashed (--) lines indicate the median, 5th and 95th percentiles for the observed concentrations 
(?). Shaded areas represent the upper, middle and lower CI for the 90% prediction intervals of simulated values (n=1000 per each 
patient time-point). 
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A B
Figure 4: Plots of measured versus population predicted (PRED; A) and individual 
predicted (IPRED; B) plasma canrenone concentrations from the final model. The 
dashed line indicates the line of perfect agreement. 
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Figure 5: Plot of conditional weighted residuals (CWRES) versus population predicted 
plasma canrenone concentration (PRED) from the final model 
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Table 1: Characteristics of patients included in the study (n=23) 
Characteristic Value 
mean (range) 
Number of patients 23 
Number of samples 101 
Number of samples per patient 4 (1-8) 
K-canrenoate dose (μmol) 10.06 (3.77 - 70.43) 
Measured canrenone conc. (μmol/L) 0.85 (0.12 - 2.26) 
GA at birth (wk)(a) 37 (25 - 41) 
PNA at inclusion (day)(a) 
(yr) 
71 (2 - 3738) 
0.195 (0.005 - 10.241) 
PMA at inclusion (wk)(a) 46.4 (37.3 - 574.0) 
Weight at inclusion (kg) 4.00 (2.16 - 28.00) 
Serum creatinine at inclusion (μmol/L) 32 (16 - 56) 
Serum albumin at inclusion (mg/dL) 33 (29 - 40) 
Haematocrit (%) 33 (26 - 40) 
Gender Male:Female 15:8 
Indication for 
K-canrenoate 
1Heart failure  
2PICU treatment of 
retained fluids 
8 (34.8%) 
15 (65.2%) 
GA group 1Very preterm (<32 wk) 
2Preterm (32 – <37 wk) 
3Full-term 
2 (8.7%) 
9 (39.1%) all at 36 wk 
12 (52.2%) 
 
Continuous variables are presented as median (range).  
Categorical variables are presented as number (percentage) 
(a) GA, gestational age; PNA, postnatal age; PMA, postmenstrual age which is normally 2 weeks longer 
than the post-conceptional age (the sum of GA and PNA). 
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Table 2: Canrenone population parameter estimates from models using fixed and 
experimentally determined exponents  
  Model with fixed 
exponents (θ1 = 0.75 
and θ2 = 1) 
Two experimentally 
determined θs (one 
for each exponent) 
One experimentally 
determined θ (θ1 for 
both exponents) 
Parameter   Estimate CV% Estimate CV% Estimate CV% 
MOFV  -98.56 - -98.46 - -97.85 - 
CL/F (L/hr/70 kg) θCL/F 11.4 10.3 12.73 26.71 14.13 38.76 
V/F (L/70 kg) θV/F 374.2 20.04 519.8 69.21 242.3 47.39 
kf (hr-1) θkf 5.25 57.84 4.48 51.11 5.79 60.01 
IIVCL/F (CV%) ωCL/F 41.06 44.25 39.4 38.7 41.67 43.83 
IIVV/F (CV%) ωV/F 45.76 60.06 97.29 42.23 44.82 78.78 
CL/F exponent θ1 0.75 - 0.798 11.92 0.833 16.44 
V/F exponent θ2 1.0 - 1.07 26.05 - - 
Residual (CV%)  34.07 23.08 31.83 23.31 34.17 23.25 
 
Model used: 
1WTCL/F (L/h)
70CL
θ
θ ⎛ ⎞= ×⎜ ⎟⎝ ⎠  and 
2WTV/F(L)
70V
θ
θ ⎛ ⎞= ×⎜ ⎟⎝ ⎠  
θ1 and θ2 are the allometric model exponents; either fixed or experimentally determined. 
 
 ωCL/F = interindividual variability in CL/F 
 ωV/F  = interindividual variability in V/F 
propσ = residual variability (proportional error model) 
CV%, percentage coefficient of variation 
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Table 3: Canrenone population parameter estimates from the final model 
developed from dataset of 23 patients, and mean parameter estimates from the 
final model fitted to the 1000 bootstrap samples  
  Final Pharmacokinetic 
model 
1000 Bootstrap 
Samples 
 
Parameter   Estimate CV% Mean CV% % diff 
CL/F (L/hr/70 kg) θCL/F 11.4 10.3 11.39 11.32 -0.07 
V/F (L/70 kg) θV/F 374.2 20.04 396.20 27.28 5.88 
kf (hr-1) θkf 5.25 57.84 5.96 59.56 13.59 
IIVCL/F (CV%) ωCL/F 41.06 44.25 40.76 30.72 -0.73 
IIVV/F (CV%) ωV/F 45.76 60.06 52.03 69.84 13.69 
Residual (CV%)  34.07 23.08 32.20 14.00 -5.48 
 
Final model: 
0.75WTCL/F (L/h)
70CL
θ ⎛ ⎞= ×⎜ ⎟⎝ ⎠  and 
WTV/F(L)
70V
θ ⎛ ⎞= ×⎜ ⎟⎝ ⎠  
 ωCL/F = interindividual variability in CL/F 
 ωV/F  = interindividual variability in V/F 
propσ = residual variability (proportional error model) 
CV%, percentage coefficient of variation 
% difference = 
bootsrap mean estimate - final model estimate 100
final model estimate
×
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Table  4: Individual Bayesian estimates obtained from the final model 
Parameter Median P5 P95 Mean ± SD Range 
CL/F (L/hr) 1.33 0.68 7.04 1.87 ± 1.56 0.67 - 7.38 
V/F (L) 19.62 13.16 193.65 34.00 ± 42.95 13.14 - 207.06 
t1/2 (hr) 12.09 4.38 19.57 12.12 ± 4.34 4.14 - 19.58 
CL/F (L/hr/kg)* 0.32 0.16 0.71 0.35 ± 0.14 0.16 - 0.73 
V/F (L/kg)* 5.35 3.35 7.80 5.36 ± 1.18 3.28 - 7.85 
 
P5, 5th percentile; P95, 95th percentile 
SD, standard deviation 
*calculated using the weight of each individual 
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